Objective. To evaluate the tolerability, efficacy, acceptance of organoleptic properties of the specialized therapeutic product, and satisfaction with its use in children with cystic fibrosis and their parents in real clinical practice. Patients and methods. This prospective follow-up study included 14 children with cystic fibrosis (10 boys and 4 girls), mean age was 9.75 years (1.4–16.8 years). The study was conducted as part of routine clinical practice at Cystic Fibrosis Centers in Astrakhan, Kazan, and Ulyanovsk. Nutritional support was provided with an isocaloric polymeric powder formula with chocolate, strawberry, and vanilla flavors; children received an average of 1.7 servings (median 2, 1–3). At the time of inclusion in the study and after an average of 16 days (median 14, 14–21) of follow-up, body weight, height, and mid-upper arm circumference (MUAC) were assessed, and body mass index (BMI), height-for-age, BMI-for-age, and MUAC-for-age Z-scores (SDS) were calculated. In addition, some laboratory parameters (hemoglobin levels, red blood cell count, white blood cell count, ESR, total protein, albumin, and C-reactive protein levels), gastrointestinal symptoms, appetite scores at baseline and at the end of followup, and satisfaction of parents and children with the product at the end of follow-up were assessed. Prior to inclusion in the study, children were able to select the flavor of the product they would then receive by taste test. The number of servings and the need to initiate or adjust enzyme replacement therapy was determined by the physician. Results. Excellent tolerability of the product was recorded, with no adverse events, steatorrhea, and allergic reactions. Body weight (p = 0.0002), BMI (p = 0.0005), and BMI Z-score (p = 0.0005) increased statistically significantly. Children highly appreciated the taste qualities of the product. The analysis of product intake diaries confirmed 100% adherence of children to the prescribed diet therapy. A total of 85% of parents and children noted that they liked or liked very much the specialized therapeutic food product and would like to continue its use. Conclusion. This study confirmed the efficacy and excellent tolerability of the specialized therapeutic food product as nutritional support in children with cystic fibrosis. Key words: cystic fibrosis, children, adolescents, diet therapy, specialized therapeutic food products, taste test